Disparities in opioid abuse treatment increased among Medicaid recipients, study finds

June 25, 2018, RAND Corporation

The number of Medicaid recipients receiving medication to treat opioid abuse increased sharply in the years after approval of a new drug, but the increase was smaller in poorer counties and areas with larger populations of black and Hispanic residents, according to a new RAND Corporation study.

While the study provides evidence that more people are receiving the medication treatment recommended for use , the findings suggest that work is needed to address disparities that developed as treatment expanded, according to researchers.

"These findings highlight the good news that is being used more widely to combat the nation's opioid epidemic," said Dr. Bradley D. Stein, the study's lead author and a senior physician scientist at RAND, a nonprofit research organization. "But it also raises concerns that there are racial/ethnic and income disparities that may prevent many individuals struggling with opioid addiction from receiving effective treatment."

The findings were published online by the journal Substance Abuse.

Opioid use disorders affect an estimated 9 out of every 1,000 Americans and opioid overdose-related deaths have quadrupled over the past 15 years. Medication-assisted treatment using methadone or buprenorphine can effectively treat opioid addiction and such care is considered the best option for people with opioid use disorders.

While methadone only can be dispensed in special clinics and commonly requires daily visits, the approval of buprenorphine in 2002 provided an alternative drug regime that can be prescribed by any specially certified physician.

In order to determine how much medication-assisted therapy expanded, RAND researchers analyzed Medicaid claims from 14 states from 2002 to 2009 to measure use of methadone and buprenorphine at the county level. Medicaid disproportionately covers individuals at higher risk for opioid use disorders and is the source of payment for more than one-third of all opioid addiction treatment episodes.

RAND researchers found that the number of Medicaid recipients who received medication-assisted treatment for opioid use disorders jumped by 62 percent during the study period. While methadone accounted for most treatment episodes, use of buprenorphine surged after its approval to account for almost one-third of treatment episodes in 2009.

Historically, there have been few sociodemographic disparities in access to treatment for substance use disorders. RAND researchers found that after accounting for whether a county was urban or rural, use of medication therapy did not vary with a county's poverty rate or ethnic/racial makeup in 2002.

However, by 2009 people who lived in counties with more poverty and higher percentages of blacks and Hispanics were significantly less likely to receive medication-assisted treatment for opioid use disorders.

In addition, researchers found that people who lived in urban counties were significantly more likely to receive medication-assisted than people who lived in rural counties, although the although the difference grew smaller during the study period.

"The expansion of medication-assisted therapy appears to have created new disparities in this area of health care," Stein said. "We need research using more-current information to better understand whether the disparity is linked to the availability of medication-assisted therapy, differences in Medicaid eligibility or some other factor, and whether it has persisted."

The states in the study are California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts, Maryland, New York, Pennsylvania, Rhode Island, Texas, Vermont and Wisconsin. The states account for nearly half of all Medicaid recipients.

Explore further: Methadone and buprenorphine decrease mortality after nonfatal overdose

Related Stories

Methadone and buprenorphine decrease mortality after nonfatal overdose

June 19, 2018
A new study out of Boston Medical Center's Grayken Center for Addiction on opioid overdose survivors indicates that two FDA approved medications to treat opioid use disorder save lives, but only three out of 10 overdose survivors ...

Medicaid expansion linked to increased prescribing of buprenorphine for opioid use disorder treatment

March 16, 2017
States where Medicaid coverage was expanded under the Affordable Care Act have had a significant increase in prescribing of buprenorphine—a medication that plays an important role in addressing the opioid epidemic, reports ...

More access to opioid treatment programs needed in Southeast, says study

March 30, 2017
In 2015, more than 30,000 Americans died from overdosing on opioids, and a new study led by the University of Georgia shows that one of the hardest hit populations-low-income Americans on Medicaid-isn't getting the help it ...

Medicaid patients continue high prescription opioid use after overdose

August 22, 2017
Despite receiving medical attention for an overdose, patients in Pennsylvania Medicaid continued to have persistently high prescription opioid use, with only slight increases in use of medication-assisted treatment, according ...

Medication-assisted treatment underused in teen opioid addicts

August 24, 2016
(HealthDay)—Resources should be increased to promote use of medication-assisted treatment of opioid addicted adolescents and young adults, according to a policy statement from the American Academy of Pediatrics (AAP) published ...

Many patients receive prescription opioids during treatment for opioid addiction

February 23, 2017
More than two in five people receiving buprenorphine, a drug commonly used to treat opioid addiction, are also given prescriptions for other opioid painkillers - and two-thirds are prescribed opioids after their treatment ...

Recommended for you

Novel botulinum toxin compound relieves chronic pain

July 18, 2018
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to research by UCL, ...

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

Opioids given too easily to children: study

July 16, 2018
(HealthDay)—Many children are prescribed powerful opioid painkillers they don't really need, putting them and those around them at risk, a new study shows.

Study reveals opioid patients face multiple barriers to treatment

July 12, 2018
In areas of the country disproportionately affected by the opioid crisis, treatment programs are less likely to accept patients paying through insurance of any type or accept pregnant women, a new Vanderbilt study found.

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.